Imaging post-177Lu-peptide receptor radionuclide therapy in a child with advanced progressive somatostatin-receptor-positive medulloblastoma

Pizzoferro, Milena; Cassano, Bartolomeo; Altini, Claudio; Cacchione, Antonella; Cefalo, Maria Giuseppina; Cannatà, Vittorio; Garganese, Maria Carmen

doi:10.1007/s00259-020-04966-w

Cited by 2 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Данные новообразования характеризуются наличием механизмов поглощения нейроаминов и/или пептидных рецепторов соматостатина (SSTR) на клеточной мембране. Эти особенности составляют основу клинического применения РНТ пептидных рецепторов с использованием, меченных радиоактивным изотопом 177 Lu аналогов соматостатина [12,13].…”

Section: основные направления основные направления педиатрической яде...unclassified

Methodological Basis of Nuclear Medicine in Pediatric

Крылов¹,

Narkevich²,

Рыжков³

2022

jour

View full text Add to dashboard Cite

Methodological foundations of nuclear medicine in pediatrics are analyzed on the basis of literature data and personal experience. The main directions of radionuclide diagnostics and radionuclide therapy in children are briefly considered. The importance of accurate determination of the optimal value of the activity of a specific radiopharmaceutical administered to a child, considering his body weight and the study protocol, was noted. A tendency to an increase in the radiation load on patients is shown due to the widespread introduction into clinical practice of hybrid installations for radionuclide studies, when using which the dose of internal radiation from radiopharmaceuticals is supplemented by the dose of external radiation from X-ray CT. The need to consider the risk of radiation-induced carcinogenesis during nuclear medical procedures, the likelihood of which in children is significantly higher than in adults, is emphasized. The technological and psychological features of these procedures in children are discussed. The necessity of revision of domestic normative documents regulating the use of means and methods of nuclear medicine in pediatrics has been substantiated.

show abstract

Section: основные направления основные направления педиатрической яде...unclassified

Methodological Basis of Nuclear Medicine in Pediatric

Крылов¹,

Narkevich²,

Рыжков³

2022

jour

View full text Add to dashboard Cite

show abstract

“…Promising results of PRRT with radiolabeled somatostatin analogs in somatostatin receptor-positive medulloblastoma [45,46].…”

Section: Meningiomasmentioning

confidence: 99%

“…Furthermore, a case of a child with an advanced SSTR-positive medulloblastoma has been recently presented by Pizzoferro et al The authors demonstrated the promising role of 177Lu-PRRT in last-line treatment in the case of SSTR-positive medulloblastoma. As pointed out by the biokinetic assessments, kidney radiation exposure may represent the main limitation of this treatment [ 46 ].…”

Section: Somatostatin Analogs and Somatostatin Receptorsmentioning

confidence: 99%

Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview

et al. 2021

View full text Add to dashboard Cite

Primary brain tumors (PBTs) are some of the most difficult types of cancer to treat, and despite advancements in surgery, chemotherapy and radiotherapy, new strategies for the treatment of PBTs are needed, especially for those with poor prognosis such as inoperable/difficult-to-reach lesions or relapsing disease. In regard to the last point, malignant primary brain tumors remain some of the most lethal types of cancer. Nuclear medicine may provide exciting new weapons and significant contributions in the treatment of PBTs. In this review, we performed literature research in order to highlight the possible role of peptide receptor radionuclide therapy (PRRT) in the treatment of PBTs with radiolabeled molecules that bind with high-affinity transmembrane receptors such as somatostatin receptors (SSTRs), neurokinin type-1 receptor and prostate-specific membrane antigen (PSMA). These receptors are overexpressed in some cancer types such as gliomas, meningiomas, pituitary tumors and medulloblastomas. A comprehensive overview of possible applications in this field will be shown, providing knowledge about benefits, feasibility, developments and limitations of PRRT in this type of tumor, also revealing new advantages in the management of the disease.

show abstract

Imaging post-177Lu-peptide receptor radionuclide therapy in a child with advanced progressive somatostatin-receptor-positive medulloblastoma

Cited by 2 publications

References 4 publications

Methodological Basis of Nuclear Medicine in Pediatric

Methodological Basis of Nuclear Medicine in Pediatric

Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview

Contact Info

Product

Resources

About